Humacyte, Inc. (NASDAQ:HUMA) Receives $8.14 Consensus Target Price from Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $8.1429.

HUMA has been the topic of several analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of Humacyte in a research note on Monday, December 1st. BTIG Research reiterated a “buy” rating and issued a $6.00 target price on shares of Humacyte in a report on Monday, February 9th. Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th.

Institutional Investors Weigh In On Humacyte

Several large investors have recently made changes to their positions in HUMA. ProShare Advisors LLC boosted its holdings in shares of Humacyte by 24.1% in the 2nd quarter. ProShare Advisors LLC now owns 31,493 shares of the company’s stock worth $66,000 after buying an additional 6,106 shares during the last quarter. Concurrent Investment Advisors LLC raised its position in Humacyte by 17.5% in the second quarter. Concurrent Investment Advisors LLC now owns 51,115 shares of the company’s stock worth $107,000 after acquiring an additional 7,615 shares during the period. Beacon Pointe Advisors LLC boosted its stake in Humacyte by 28.6% in the second quarter. Beacon Pointe Advisors LLC now owns 36,000 shares of the company’s stock valued at $75,000 after acquiring an additional 8,000 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Humacyte by 50.3% during the 4th quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock valued at $33,000 after acquiring an additional 11,411 shares during the period. Finally, Independent Advisor Alliance increased its stake in shares of Humacyte by 49.4% during the 3rd quarter. Independent Advisor Alliance now owns 36,240 shares of the company’s stock worth $63,000 after purchasing an additional 11,991 shares during the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Trading Up 6.5%

NASDAQ:HUMA opened at $1.15 on Tuesday. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90. Humacyte has a one year low of $0.88 and a one year high of $3.94. The company has a market cap of $215.36 million, a PE ratio of -5.00 and a beta of 1.93. The firm has a 50-day moving average of $1.07 and a 200-day moving average of $1.41.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.